-
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
-
EMA Takes Action on Metamizole-Induced Risks
EMA
The EMA has issued new recommendations to mitigate agranulocytosis risks associated with metamizole, urging increased awareness among healthcare providers and patients. Symptoms include fever and sore throat; immediate medical attention is crucial.
-
-
-
EMA's CHMP June 2024 Approvals and Recommendations
EMA
In June 2024, the EMA's CHMP recommended 10 new medicines for approval, including Balversa for urothelial carcinoma and Eurneffy, the first nasal spray for allergic reactions. Notable approvals also include mResvia, an mRNA vaccine for RSV, and treatments for various cancers and rare diseases.
-
-
枝江市|
德州市|
荥阳市|
浏阳市|
开平市|
闽侯县|
大兴区|
德格县|
南通市|
荃湾区|
沙洋县|
富蕴县|
成武县|
琼中|
周口市|
青冈县|
夏河县|
金溪县|
尖扎县|
汤原县|
双流县|
中超|
顺昌县|
宕昌县|
正镶白旗|
邻水|
香港
|
镇江市|
思南县|
武强县|
会昌县|
水富县|
屏东县|
芮城县|
苍南县|
伊川县|
柳州市|
兴仁县|
麻江县|
合阳县|
神木县|